July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Pretreatment factors in managing protocol with aflibercept in patients with diabetic macular edema
Author Affiliations & Notes
  • Saori Tanaka
    Kobe City Eye Hospital, Kobe, Japan
    Kobe City Medical Center General Hospital, Japan
  • Noriko Miyamoto
    Kobe City Eye Hospital, Kobe, Japan
    Kobe City Medical Center General Hospital, Japan
  • Sentaro Kusuhara
    Kobe University Graduate School of Medicine, Japan
  • Hisashi Iwami
    Hyogo College of Medicine, Japan
  • Shogo Yamamoto
    Kobe City Eye Hospital, Kobe, Japan
    Kobe City Medical Center General Hospital, Japan
  • Shin Yoshitake
    Kobe City Eye Hospital, Kobe, Japan
    Kobe City Medical Center General Hospital, Japan
  • Yuji Hirota
    Kobe University Graduate School of Medicine, Japan
  • Makoto Nakamura
    Kobe University Graduate School of Medicine, Japan
  • Masahiro Ikeda
    Kobe University Graduate School of Medicine, Japan
  • Fumi Gomi
    Hyogo College of Medicine, Japan
  • Yasuo Kurimoto
    Kobe City Eye Hospital, Kobe, Japan
    Kobe City Medical Center General Hospital, Japan
  • Footnotes
    Commercial Relationships   Saori Tanaka, None; Noriko Miyamoto, None; Sentaro Kusuhara, None; Hisashi Iwami, None; Shogo Yamamoto, None; Shin Yoshitake, None; Yuji Hirota, None; Makoto Nakamura, None; Masahiro Ikeda, None; Fumi Gomi, None; Yasuo Kurimoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2604. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saori Tanaka, Noriko Miyamoto, Sentaro Kusuhara, Hisashi Iwami, Shogo Yamamoto, Shin Yoshitake, Yuji Hirota, Makoto Nakamura, Masahiro Ikeda, Fumi Gomi, Yasuo Kurimoto; Pretreatment factors in managing protocol with aflibercept in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2604. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti-vascular endothelial growth factor (VEGF) agents have been the mainstay of treatment for diabetic macular edema (DME). However, frequent injections of anti-VEGF agent create a burden to both patients and physicians. The predictors of outcome using anti-VEGF agents would be helpful for patients counseling before treatment. Accordingly, we aimed to search pre-treatment factors which can effectively predict visual and structural outcomes after intravitreal aflibercept injection (IVA) for DME.

Methods : We retrospectively reviewed the medical records of 32 eyes of 32 patients with DME (14 men and 18 women, the mean age was 66 years) who were treated with IVA (3 monthly induction and as need thereafter) from January 2016 to August 2017 at 3 hospitals in Hyogo Prefecture. We analyzed the correlations between changes in best corrected visual acuity (BCVA) (logMAR unit) or central retinal thickness (CRT) and various pretreatment factors including medical history, blood or urinary test results, and parameters on optical coherence tomography.

Results : There was a significant correlation between the change in BCVA and the history of diabetes mellitus (r=0.443, P=0.012), dyslipidemia (r=0.450, P=0.011), serous retinal detachment (r=-0.390, P=0.027), pars plana vitrectomy (r=-0.392, P=0.026), ellipsoid zone (EZ)(r=-0.399, P=0.024), and external limiting membrane (ELM) (r=-0.433, P=0.013) at 3 months and ELM(r=-0.351, P=0.049) at 12 months. While, there was a correlation between the change in CRT and sub-Tenon’s injection of triamcinolone acetonide (r=0.416, P=0.018) at 3 months, and dyslipidemia (r=0.548, P=0.001) at 12 months.

Conclusions : In addition to known factors such as EZ and ELM, dyslipidemia showed a close correlation to not only BCVA but also CRT after IVA treatment. Therefore, serum lipid level might be worth being considered before treatment of DME.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×